好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Early Ischemic Changes on Serial CT Imaging in Acute Ischemic Stroke
Cerebrovascular Disease and Interventional Neurology
P6 - Poster Session 6 (11:30 AM-1:00 PM)
15-029

EIC on NCCT can appear within 6 hours of last known normal (LKN), and can be quantified using the Alberta Stroke Program Early CT Score (ASPECTS). However, there is lack of data describing when EIC first appear.

We leveraged our Mobile Stroke Unit (MSU) to determine the incidence of Early Ischemic Changes (EIC) on serial non-contrast computed tomography (NCCT).

Prospectively derived data from tissue plasminogen activator (tPA) eligible patients on MSU who had serial NCCT scans within 1 and 6 hours of LKN, and definite strokes on subsequent testing. EIC, defined as ASPECTS ≤ 7, were correlated to time from LKN, stroke severity (National Institutes of Health Stroke Scale, NIHSS), and large vessel occlusion (LVO) on neuroimaging. Scans were graded by Vascular Neurology fellow, with random scans compared with Vascular Neurology attending (Κ=0.69).

57 patients met above inclusion criteria. Of these, 54 had NCCT within 1 hour (median 46 minutes, IQR 39-52) and 31 within 6 hours (median 105 minutes, IQR 90-139) of LKN with sufficient diagnostic quality. Mean ASPECTS was 9.2 and 8.7 for each time point with average NIHSS 14.9. EIC were identified in 4 patients (7%; e.g. ASPECTS 6, 6, 7, 7) within 1 hour and 5 patients (16%; e.g. ASPECTS 2, 3, 7, 7, 7) within 6 hours of LKN. 2 patients had substantial change in ASPECT score (≥ 3 points) on NCCT within 6 hours. There was no association between ASPECTS score and time from LKN to CT (within 1 hour p=0.63, within 6 hours p=0.96). EIC detected within 6 hours correlated to presence of LVO (p=0.01) and stroke severity (p=0.03).

Though limited by small sample, substantial ASPECTS decay within 6 hours of LKN is rare. Close scrutiny of NCCT for EIC within this timeframe may not be necessary for determining eligibility for endovascular thrombectomy.

Authors/Disclosures
Alexandra L. Czap, MD (University of Texas Health Science Center At Houston)
PRESENTER
The institution of Dr. Czap has received research support from SVIN. The institution of Dr. Czap has received research support from AAN.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Ritvij Bowry, MD Dr. Bowry has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astrazeneca.
James C. Grotta, MD, FAAN (Memorial Hermann Hospital Life Flight) Dr. Grotta has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Frazer Ltd. Dr. Grotta has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Haemonetics. Dr. Grotta has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acticor. Dr. Grotta has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prolong Pharma. Dr. Grotta has received publishing royalties from a publication relating to health care. Dr. Grotta has received publishing royalties from a publication relating to health care.